Glaxo SmithKline France
- A02 - Agentes para el tratamiento de alteraciones causadas por ácidos
- ZANTAC effervescent tablet 150 mg
- B01 - Agentes antitrombóticos
- ARIXTRA solution for injection 10 mg/0.8 ml
- ARIXTRA solution for injection 2.5 mg/0.5 ml
- ARIXTRA solution for injection 5 mg/0.4 ml
- ARIXTRA solution for injection 7.5 mg/0.6 ml
- R03 - Agentes contra padecimientos obstructivos de las vías respiratorias
- FLIXOTIDE EVOHALER CFC FREE pressurised inhalation, suspension 125 µg/dose
- FLIXOTIDE EVOHALER CFC FREE pressurised inhalation, suspension 50 µg/dose
- VENTOLIN EVOHALER pressurised inhalation, suspension 100 µg/dose